{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:04:23Z","timestamp":1792839863546,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["20JCJQJC00280"],"award-info":[{"award-number":["20JCJQJC00280"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["21JCYBJC01160"],"award-info":[{"award-number":["21JCYBJC01160"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171777"],"award-info":[{"award-number":["82171777"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.msard.2025.106314","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T11:36:05Z","timestamp":1738668965000},"page":"106314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effectiveness and safety of glucocorticoids bridging rituximab in neuromyelitis spectrum disorder"],"prefix":"10.1016","volume":"95","author":[{"given":"Chunyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moli","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0659-4597","authenticated-orcid":false,"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106314_bib0001","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106314_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.608149","article-title":"Early treatment initiation with oral prednisolone for relapse prevention alleviates depression and fatigue in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"12","author":"Akaishi","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0003","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/NXI.0000000000000985","article-title":"Pain, depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 aqp4 antibody-seropositive patients","volume":"8","author":"Ayzenberg","year":"2021","journal-title":"Neurol. Neuroim. Neuroinf."},{"key":"10.1016\/j.msard.2025.106314_bib0004","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and mog antibody disease","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106314_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104321","article-title":"Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: an exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2\/3 trial","volume":"86","author":"Bennett","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.msard.2025.106314_bib0006","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2025.106314_bib0007","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psyc."},{"key":"10.1016\/j.msard.2025.106314_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin american consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106314_bib0009","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","article-title":"Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders","volume":"174","author":"Ciron","year":"2018","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0010","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1756285616632653","article-title":"An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica","volume":"9","author":"Collongues","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106314_bib0011","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0012","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12974-022-02420-2","article-title":"Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study","volume":"19","author":"Demuth","year":"2022","journal-title":"J. Neuroinflam."},{"key":"10.1016\/j.msard.2025.106314_bib0013","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0014","doi-asserted-by":"crossref","first-page":"e20824","DOI":"10.1097\/MD.0000000000020824","article-title":"Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: a single-center, randomized, double-blind clinical trial","volume":"99","author":"Hua","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.msard.2025.106314_bib0015","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106314_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2018.11.022","article-title":"Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder","volume":"130","author":"Kim","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.msard.2025.106314_bib0017","article-title":"Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from Sakurasky and Sakurastar","volume":"10","author":"Kleiter","year":"2022","journal-title":"Neurol. Neuroim. Neuroinf."},{"key":"10.1016\/j.msard.2025.106314_bib0018","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106314_bib0019","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/09114300.2018.1451593","article-title":"Era of steroid sparing in the management of immune-mediated inflammatory diseases","volume":"41","author":"Kondo","year":"2018","journal-title":"Immunol. Med."},{"key":"10.1016\/j.msard.2025.106314_bib0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0021","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577528","article-title":"Low-dose rituximab treatment for new-onset generalized myasthenia gravis","volume":"354","author":"Li","year":"2021","journal-title":"J. Neuroim."},{"key":"10.1016\/j.msard.2025.106314_bib0023","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0024","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","article-title":"Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels","volume":"18","author":"Nakashima","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2025.106314_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/460825","article-title":"Neuromyelitis optica: an antibody-mediated disorder of the central nervous system","volume":"2012","author":"Oh","year":"2012","journal-title":"Neurol. Res. Int."},{"key":"10.1016\/j.msard.2025.106314_bib0026","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol. Neuroim. Neuroinf."},{"key":"10.1016\/j.msard.2025.106314_bib0027","doi-asserted-by":"crossref","first-page":"e06811","DOI":"10.1016\/j.heliyon.2021.e06811","article-title":"PLEX: The best first-line treatment in nmosd attacks experience at a single center in Colombia","volume":"7","author":"Restrepo-Aristiz\u00e1bal","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.msard.2025.106314_bib0028","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","article-title":"Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study","volume":"266","author":"Shaygannejad","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0029","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis","volume":"268","author":"Siritho","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/jnnp-2022-330086","article-title":"Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"94","author":"Spagni","year":"2023","journal-title":"J. Neurol. Neuros. Psych."},{"key":"10.1016\/j.msard.2025.106314_bib0031","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/rheumatology\/kez213","article-title":"Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA","volume":"58","author":"Stouten","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.msard.2025.106314_bib0032","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106314_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102869","article-title":"Effectiveness of treatments in neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature","volume":"50","author":"Velasco","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106314_bib0035","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.3390\/ijms22062801","article-title":"Neuromyelitis Optica spectrum disorder treatment-current and future prospects","volume":"22","author":"Waliszewska-Pros\u00f3\u0142","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106314_bib0036","article-title":"Neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: outcome prediction models","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106314_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103772","article-title":"Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in Sakurasky: a case series","volume":"61","author":"Yamamura","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106314_bib0038","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106314_bib0039","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00415-022-11364-9","article-title":"A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder","volume":"270","author":"Yang","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106314_bib0040","doi-asserted-by":"crossref","first-page":"e1070","DOI":"10.1212\/NXI.0000000000001070","article-title":"B-Cell Compartmental features and molecular basis for therapy in autoimmune disease","volume":"8","author":"Zhang","year":"2021","journal-title":"Neurol. Neuroim. Neuroinf."},{"key":"10.1016\/j.msard.2025.106314_bib0041","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta. Neurol. Belg"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:29:16Z","timestamp":1778840956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":41,"alternative-id":["S2211034825000586"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106314","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of glucocorticoids bridging rituximab in neuromyelitis spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106314"}}